Sometime this month the UK Competition and Markets Authority is expected to decide whether Pfizer Inc. and Flynn Pharma Ltd. breached competition law by charging "excessive and unfair" prices for the anti-epileptic, phenytoin sodium capsules.
The decision, the latest stage of a formal investigation begun by the CMA in 2013, was originally to have been...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?